Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348276 | 0.88 | KMT2A (0.49) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL10169311 | 0.88 | KMT2A (0.49) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL31369639 | 0.86 | KMT2A (0.53) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL31369977 | 0.86 | KMT2A (0.53) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL10169075 | 0.86 | KMT2A (0.49) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL6356022 | 0.86 | KMT2A (0.49) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL6383724 | 0.84 | KMT2A (0.50) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL2384012 | 0.84 | KMT2A (0.50) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL12088709 | 0.84 | KMT2A (0.50) | KMT2AEPHX2CASP3 | |
| SCHEMBL119535 | 0.84 | KMT2A (0.50) | KMT2AEPHX2FABP7FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | KMT2A 3736/4885EPHX2 2383/4885CNR2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.